Skip to main content Skip to journal navigation menu Skip to site footer
contact@ukscip.com
Review

Immunoinflammatory and Metabolic Drivers of Endometrial Hyperplasia: From Unopposed Estrogen to Precision Medicine

Arystanbek Atykanov ORCID ,  Albina Aktanbekova ,  Argen Alymkulov ORCID ,  Altynai Zhumabekova ORCID
    Received: 24 April 2026; Revised: 11 May 2026; Accepted: 20 August 2026; Published: 14 September 2026

    Abstract

    Endometrial hyperplasia (EH) is a precursor to carcinoma, with the risk amplified by obesity, polycystic ovary syndrome, insulin resistance, and delayed childbearing through estrogen excess and anovulatory “unopposed estrogen” states. This review synthesizes endocrine, metabolic, molecular, diagnostic, and therapeutic evidence in EH, distinguishing findings from unvalidated mechanisms to inform biomarker development without displacing histopathology. The literature was searched in PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar (January 2000–March 2026; 2020 onward) using terms spanning EH/Endometrial intraepithelial neoplasia, cytokines, oxidative stress, PI3K/AKT/mTOR, obesity, microbiome, and biomarkers; English-language studies, reviews, meta-analyses, and guidelines were weighted toward human EH data, guided by the Scale, without a formal risk-of-bias tool. Evidence supports endocrine driving: estrogen receptor signaling promotes proliferation via cyclins and PI3K/AKT and MAPK pathways, whereas progesterone loss facilitates persistence. EH shows elevated interleukin-6 (IL-6), TNF-α, IL-1β, and IL-8, engaging NF-κB/STAT3 circuits, although limited. Oxidative stress may affect progression through reactive oxygen species-driven peroxidation and DNA (Deoxyribonucleic Acid) damage. Recurrent alterations (PTEN loss; PIK3CA, KRAS, and β-catenin changes) inform the stratification and therapy resistance in atypical EH/Endometrial intraepithelial neoplasia. Histopathology remains central, with immunohistochemistry. Clinically, levonorgestrel-releasing intrauterine system shows superior regression compared to progestins, and metformin is adjunctive. The rate of occult carcinoma at hysterectomy was 45.3%. Fertility-sparing levonorgestrel-releasing intrauterine system is effective but carries a risk of disease progression/recurrence. Overall, EH is hormone-driven and involves metabolic, inflammatory, oxidative, and molecular modifiers. Precision care requires the prospective validation of biomarker panels beyond histology and clinical risk.

    Keywords

    References

    1. 1. Boureka, E.; Tsakiridis, I.; Kapetanios, G.; et al. Management of Endometrial Hyperplasia: A Comparative Review of Guidelines. Cancers 2025, 17, 3143.
    2. 2. Chandra, V.; Kim, J.J.; Benbrook, D.M.; et al. Therapeutic options for management of endometrial hyperplasia. J. Gynecol. Oncol. 2016, 27, e8.
    3. 3. Russo, M.; Newell, J.M.; Budurlean, L.; et al. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer 2020, 126, 2775–2783.
    4. 4. Doherty, M.T.; Sanni, O.B.; Coleman, H.G.; et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One 2020, 15, e0232231.
    5. 5. Park, J.C.; Lim, S.Y.; Jang, T.K.; et al. Endometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome. Clin. Exp. Reprod. Med. 2011, 38, 42–46.
    6. 6. Ordeanu, I.M.; Busuioc, C.J.; Văduva, C.C.; et al. Obesity as a Catalyst for Endometrial Hyperplasia and Cancer Progression: A Narrative Review of Epidemiology, Molecular Pathways, and Prevention. Biomedicines 2025, 13, 2612.
    7. 7. Yuan, D.Z.; Ding, X.L.; Yu, H.L.; et al. Progesterone-induced cyclin G1 inhibits the proliferation of endometrial epithelial cell and its possible molecular mechanism. Horm. Metab. Res. 2014, 46, 761–767.
    8. 8. Stute, P.; Neulen, J.; Wildt, L. The impact of micronized progesterone on the endometrium: A systematic review. Climacteric 2016, 19, 316–328.
    9. 9. Xue, Z.; Li, J.; Feng, J.; et al. Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium. Front. Physiol. 2021, 12, 788772.
    10. 10. Glynne, S.; Kamal, A.; Neville, A.; et al. Endometrial thickness and pathology in postmenopausal women with bleeding on transdermal 17β-estradiol plus body-identical progesterone. Arch. Gynecol. Obstet. 2025, 312, 1705–1717.
    11. 11. Emons, G.; Mustea, A.; Tempfer, C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers 2020, 12, 2535.
    12. 12. Coopes, A.; Henry, C.E.; Llamosas, E.; et al. An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target. Endocr. Relat. Cancer 2018, 25, R647–R662.
    13. 13. Zheng, H.T.; Lou, M.W.C.; Dugué, P.A.; et al. Circulating inflammatory markers and risk of endometrial cancer: A systematic review and meta-analysis. Cancer Epidemiol. 2024, 93, 102662.
    14. 14. Rossi, J.F.; Lu, Z.Y.; Massart, C.; et al. Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer. Front. Immunol. 2021, 12, 595722.
    15. 15. Moshayedi, N.; Clair, K.; Francoeur, A.A. Obesity management in the setting of endometrial cancer and hyperplasia: A narrative review. Gynecol. Oncol. Rep. 2025, 61, 101929.
    16. 16. Branco, A.C.C.C.; Yoshikawa, F.S.Y.; Pietrobon, A.J.; et al.. Role of Histamine in Modulating the Immune Response and Inflammation. Mediators Inflamm. 2018, 2018, 9524075.
    17. 17. Obeagu, E.I. A narrative review on the role of IL-1β, IL-8, and the endometrial matrix in heavy menstrual bleeding pathogenesis. Ann. Med. Surg. 2025, 87, 7224–7231.
    18. 18. Bhol, N.K.; Bhanjadeo, M.M.; Singh, A.K.; et al. The interplay between cytokines, inflammation, and antioxidants: Mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomed. Pharmacother. 2024, 178, 117177.
    19. 19. Wang, H.Q.; Jia, L.; Li, Y.T.; et al. Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia. J. Cell. Physiol. 2019, 234, 13994–14006.
    20. 20. Nishida, A.; Andoh, A. The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis. Cells 2025, 14, 488.
    21. 21. Che, Q.; Xiao, X.; Xu, J.; et al. 17β-Estradiol promotes endometrial cancer proliferation and invasion through IL-6 pathway. Endocr. Connect. 2019, 8, 961–968.
    22. 22. Sadžak, A.; Mravljak, J.; Maltar-Strmečki, N.; et al. The Structural Integrity of the Model Lipid Membrane during Induced Lipid Peroxidation: The Role of Flavonols in the Inhibition of Lipid Peroxidation. Antioxidants 2020, 9, 430.
    23. 23. Mohideen, K.; Chandrasekar, K.; Ramsridhar, S.; et al. Assessment of Oxidative Stress by the Estimation of Lipid Peroxidation Marker Malondialdehyde (MDA) in Patients with Chronic Periodontitis: A Systematic Review and Meta-Analysis. Int. J. Dent. 2023, 2023, 6014706.
    24. 24. Hagan, M.L.; Tuladhar, A.; Yu, K.; et al. Osteocyte Sptbn1 Deficiency Alters Cell Survival and Mechanotransduction Following Formation of Plasma Membrane Disruptions (PMD) from Mechanical Loading. Calcif. Tissue Int. 2024, 115, 725–743.
    25. 25. Tuladhar, A.; Shaver, J.C.; McGee, W.A.; et al. Prkd1 regulates the formation and repair of plasma membrane disruptions (PMD) in osteocytes. Bone 2024, 186, 117147.
    26. 26. Sul, O.J.; Ra, S.W. Quercetin Prevents LPS-Induced Oxidative Stress and Inflammation by Modulating NOX2/ROS/NF-kB in Lung Epithelial Cells. Molecules 2021, 26, 6949.
    27. 27. Venkatachalam, G.; Surana, U.; Clément, M.V. Replication stress-induced endogenous DNA damage drives cellular senescence induced by a sub-lethal oxidative stress. Nucleic Acids Res. 2017, 45, 10564–10582.
    28. 28. Souliotis, V.L.; Vlachogiannis, N.I.; Pappa, M.; et al. DNA Damage Response and Oxidative Stress in Systemic Autoimmunity. Int. J. Mol. Sci. 2019, 21, 55.
    29. 29. Endale, H.T.; Tesfaye, W.; Mengstie, T.A. ROS induced lipid peroxidation and their role in ferroptosis. Front. Cell Dev. Biol. 2023, 11, 1226044.
    30. 30. Kovalenko, T.F.; Morozova, K.V.; Ozolinya, L.A.; et al. The PTENP1 Pseudogene, Unlike the PTEN Gene, Is Methylated in Normal Endometrium, As Well As in Endometrial Hyperplasias and Carcinomas in Middle-Aged and Elderly Females. Acta Naturae 2018, 10, 43–50.
    31. 31. Harkins, S.K.; Skalski, H.J.; Arendt, A.; et al. Abstract B028: Epithelial-specific loss of PIK3R1 in a murine model result in endometrial hyperplasia. Clin. Cancer Res. 2024, 30, B028.
    32. 32. Clemente-Suárez, V.J.; Redondo-Flórez, L.; Beltrán-Velasco, A.I.; et al. The Role of Adipokines in Health and Disease. Biomedicines 2023, 11, 1290.
    33. 33. Lin, T.Y.; Chiu, C.J.; Kuan, C.H.; et al. IL-29 promoted obesity-induced inflammation and insulin resistance. Cell. Mol. Immunol. 2020, 17, 369–379.
    34. 34. Huh, J.Y.; Park, J.; Kim, J.I.; et al. Deletion of CD1d in Adipocytes Aggravates Adipose Tissue Inflammation and Insulin Resistance in Obesity. Diabetes 2017, 66, 835–847.
    35. 35. Lee, H.H.; Jeong, G.W.; Ye, B.J.; et al. TonEBP in Myeloid Cells Promotes Obesity-Induced Insulin Resistance and Inflammation Through Adipose Tissue Remodeling. Diabetes 2022, 71, 2557–2571.
    36. 36. Liao, Z.; Wang, Y.; Hu, C.; et al. Adipocyte ZAG improves obesity-triggered insulin resistance by reshaping macrophages populations in adipose tissue. Int. Immunopharmacol. 2025, 152, 114414.
    37. 37. Morielli, A.R.; Kokts-Porietis, R.L.; Benham, J.L.; et al. Associations of insulin resistance and inflammatory biomarkers with endometrial cancer survival: The Alberta endometrial cancer cohort study. Cancer Med. 2022, 11, 1701–1711.
    38. 38. Uccella, S.; Zorzato, P.C.; Dababou, S.; et al. Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. Medicina 2022, 58, 1256.
    39. 39. Chung, S.S.; Wu, Y.; Okobi, Q.; et al. Proinflammatory Cytokines IL-6 and TNF-α Increased Telomerase Activity through NF-κB/STAT1/STAT3 Activation, and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells. Mediators Inflamm. 2017, 2017, 5958429.
    40. 40. Li, L.; Gao, H.; Pan, L.; et al. All-trans retinoic acid inhibits epithelial-to-mesenchymal transition (EMT) through the down-regulation of IL-6 in endometriosis. Ann. Palliat. Med. 2021, 10, 11348–11361.
    41. 41. Matsuda, T. The Physiological and Pathophysiological Role of IL-6/STAT3-Mediated Signal Transduction and STAT3 Binding Partners in Therapeutic Applications. Biol. Pharm. Bull. 2023, 46, 364–378.
    42. 42. Ding, Y.; Hong, Y.; Zou, Y.; et al. Bushen Zhuyun Decoction Enhances Endometrial Receptivity via the IL-6/STAT3 Signaling Pathway in Rats. Comb. Chem. High Throughput Screen. 2025, 28, 2721–2736.
    43. 43. Sahin, E.; Eraslan Sahin, M.; Dolanbay, M.; et al. Induction of apoptosis by metformin and progesterone in estrogen-induced endometrial hyperplasia in rats: Involvement of the bcl-2 family proteins. Gynecol. Endocrinol. 2018, 34, 433–436.
    44. 44. Zhu, Y.; Shen, J.; Gao, L.; et al. Estrogen promotes fat mass and obesity-associated protein nuclear localization and enhances endometrial cancer cell proliferation via the mTOR signaling pathway. Oncol. Rep. 2016, 35, 2391–2397.
    45. 45. Ge, Y.; Ni, X.; Li, J.; et al. Roles of estrogen receptor α in endometrial carcinoma (Review). Oncol. Lett. 2023, 26, 530.
    46. 46. Yu, K.; Huang, Z.Y.; Xu, X.L.; et al. Estrogen Receptor Function: Impact on the Human Endometrium. Front. Endocrinol. 2022, 13, 827724.
    47. 47. Sahoo, S.S.; Zhang, X.D.; Hondermarck, H.; et al. The Emerging Role of the Microenvironment in Endometrial Cancer. Cancers 2018, 10, 408.
    48. 48. Vandooren, J.; Itoh, Y. Alpha-2-Macroglobulin in Inflammation, Immunity and Infections. Front. Immunol. 2021, 12, 803244.
    49. 49. O'Hagan-Wong, K.; Nadeau, S.; Carrier-Leclerc, A.; et al. Increased IL-6 secretion by aged human mesenchymal stromal cells disrupts hematopoietic stem and progenitor cells' homeostasis. Oncotarget 2016, 7, 13285–13296.
    50. 50. Pacifico, T.; Stolfi, C.; Tomassini, L.; et al. Rafoxanide negatively modulates STAT3 and NF-κB activity and inflammation-associated colon tumorigenesis. Cancer Sci. 2024, 115, 3596–3611.
    51. 51. Du, Y.; Yang, J.; Su, T.; et al. Lipid mediator lipoxin A4 and its analog BML-111 exert antitumor effects in melanoma. Ann. Transl. Med. 2021, 9, 802.
    52. 52. Hirahara, L.; Takase-Minegishi, K.; Kirino, Y.; et al. The Roles of Monocytes and Macrophages in Behçet's Disease with Focus on M1 and M2 Polarization. Front. Immunol. 2022, 13, 852297.
    53. 53. Gallelli, C.A.; Calcagnini, S.; Romano, A.; et al. Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues. Antioxidants 2018, 7, 93.
    54. 54. Cui, L.; Zheng, F.; Zhang, M.; et al. Selenium suppressed the LPS-induced oxidative stress of bovine endometrial stromal cells through Nrf2 pathway with high cortisol background. J. Anim. Sci. 2024, 102, skae260.
    55. 55. Nguyen-Powanda, P.; Robaire, B. Aging and oxidative stress alter DNA repair mechanisms in male germ cells of superoxide dismutase-1 null mice. Biol. Reprod. 2021, 105, 944–957.
    56. 56. Peixoto, M.S.; de Vasconcelos E Souza, A.; Andrade, I.S.; et al. Hypothyroidism induces oxidative stress and DNA damage in breast. Endocr. Relat. Cancer 2021, 28, 505–519.
    57. 57. Divekar, S.; Kritzer, R.; Shu, H.; et al. Systemic DNA Damage and Repair Activity Vary by Race in Breast Cancer Survivors. Cancers 2024, 16, 1807.
    58. 58. Gentile, F.; Arcaro, A.; Pizzimenti, S.; et al. DNA damage by lipid peroxidation products: Implications in cancer, inflammation and autoimmunity. AIMS Genet. 2017, 4, 103–137.
    59. 59. Xue, Y.; Dong, Y.; Lou, Y.; et al. PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia. J. Gynecol. Oncol. 2023, 34, e53.
    60. 60. Westin, S.N.; Ju, Z.; Broaddus, R.R.; et al. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol. Oncol. 2015, 9, 1694–1703.
    61. 61. Yu, K.; Wang, Y. The Advance and Correlation of KRAS Mutation with the Fertility-Preservation Treatment of Endometrial Cancer in the Background of Molecular Classification Application. Pathol. Oncol. Res. 2021, 27, 1609906.
    62. 62. Malentacchi, F.; Turrini, I.; Sorbi, F.; et al. Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer. Oncol. Rep. 2019, 41, 1560–1574.
    63. 63. Karlsson, T.; Krakstad, C.; Tangen, I.L.; et al. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Oncotarget 2017, 8, 3881–3894.
    64. 64. Eritja, N.; Navaridas, R.; Ruiz-Mitjana, A.; et al. Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation. Cancers 2021, 13, 4990.
    65. 65. Mollova-Kyosebekirova, A.; Uchikova, E.; Mihaylova, A.; et al. The Role of Microsatellite Instability in Endometrial Hyperplasia and Risk of Carcinoma Development. Biomedicines 2025, 13, 2953.
    66. 66. Worrell, J.C.; MacLeod, M.K.L. Stromal-immune cell crosstalk fundamentally alters the lung microenvironment following tissue insult. Immunology 2021, 163, 239–249.
    67. 67. Szebeni, G.J.; Vizler, C.; Kitajka, K.; et al. Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters. Mediators Inflamm. 2017, 2017, 9294018.
    68. 68. Jiang, P.; Yu, J.; Zheng, Y.; et al. Prognostic significance and immune infiltration analysis of HMGA2 in endometrial cancer. Front. Immunol. 2025, 16, 1559278.
    69. 69. Wang, Y.; Liu, N.; Guo, X.; et al. The immune microenvironment in endometrial carcinoma: mechanisms and therapeutic targeting. Front. Immunol. 2025, 16, 1586315.
    70. 70. Chandran, S.; Cairns, M.T.; O'Brien, M.; et al. Effects of combined progesterone and 17β-estradiol treatment on the transcriptome of cultured human myometrial smooth muscle cells. Physiol. Genomics 2016, 48, 50–61.
    71. 71. Di Ceglie, I.; Carnevale, S.; Rigatelli, A.; et al. Immune cell networking in solid tumors: Focus on macrophages and neutrophils. Front. Immunol. 2024, 15, 1341390.
    72. 72. Zhang, B.; Mohd Sahardi, N.F.N.; Di, W.; et al. The Gut-Endometrium Axis: Exploring the Role of Microbiome in the Pathogenesis and Treatment of Endometrial Cancer-A Narrative Review. Cancers 2025, 17, 1044.
    73. 73. Schreurs, M.P.H.; de Vos van Steenwijk, P.J.; Romano, A.; et al. How the Gut Microbiome Links to Menopause and Obesity, with Possible Implications for Endometrial Cancer Development. J. Clin. Med. 2021, 10, 2916.
    74. 74. Liang, J.; Li, M.; Zhang, L.; et al. Analysis of the microbiota composition in the genital tract of infertile patients with chronic endometritis or endometrial polyps. Front. Cell. Infect. Microbiol. 2023, 13, 1125640.
    75. 75. Shivanandappa, N.; Swamy, S.N.; Kumar, S.S.; et al. Aberrant promoter hypermethylation of RAR-β in endometrial carcinoma—An Indian study. Int. J. Med. Res. Rev. 2021, 9, 160–166.
    76. 76. Caplakova, V.; Babusikova, E.; Blahovcova, E.; et al. DNA Methylation Machinery in the Endometrium and Endometrial Cancer. Anticancer Res. 2016, 36, 4407–4420.
    77. 77. van den Helder, R.; Wever, B.M.M.; van Trommel, N.E.; et al. Non-invasive detection of endometrial cancer by DNA methylation analysis in urine. Clin. Epigenetics 2020, 12, 165.
    78. 78. Makabe, T.; Arai, E.; Hirano, T.; et al. Genome-wide DNA methylation profile of early-onset endometrial cancer: Its correlation with genetic aberrations and comparison with late-onset endometrial cancer. Carcinogenesis 2019, 40, 611–623.
    79. 79. Chen, Q.; Li, H.; Liu, Y.; et al. Epigenetic Regulation of Immune and Inflammatory Responses in Rheumatoid Arthritis. Front. Immunol. 2022, 13, 881191.
    80. 80. Oncu, N.; Buhur, A.; Erkinuresin, T. Evaluation of diagnostic accuracy of Pipelle endometrial biopsy using sensitivity and specificity in women with abnormal uterine bleeding. Medicine 2026, 105, e47145.
    81. 81. Wang, L.; Piskorz, A.; Bosse, T.; et al. Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. Int. J. Gynecol. Pathol. 2022, 41, 12–19.
    82. 82. Jiang, X.; Jia, H.; Zhang, Z.; et al. The Feasibility of Combining ADC Value With Texture Analysis of T2WI, DWI and CE-T1WI to Preoperatively Predict the Expression Levels of Ki-67 and p53 of Endometrial Carcinoma. Front. Oncol. 2022, 11, 805545.
    83. 83. Rewcastle, E.; Varhaugvik, A.E.; Gudlaugsson, E.; et al. Assessing the prognostic value of PAX2 and PTEN in endometrial carcinogenesis. Endocr. Relat. Cancer 2018, 25, 981–991.
    84. 84. Hamza, M.S.; Ramadan, E.; Salama, S.A. Glucose and fatty acid metabolism involved in the protective effect of metformin against ulipristal-induced endometrial changes in rats. Sci. Rep. 2021, 11, 8863.
    85. 85. Stewart, K.I.; Yates, M.S.; Westin, S.N. Pushing the envelope: Expanding fertility sparing treatment of endometrial cancer. J. Gynecol. Oncol. 2020, 31, e82.
    86. 86. Leone Roberti Maggiore, U.; Martinelli, F.; Dondi, G.; et al. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: A retrospective study. J. Gynecol. Oncol. 2019, 30, e57.
    87. 87. Lv, X.; Guo, L.; Wang, C. Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia. J. Gynecol. Oncol. 2024, 35, e27.
    88. 88. He, Y.; Wang, J.; Wang, Y.; et al. Maintenance Therapy Can Improve the Oncologic Prognosis and Obstetrical Outcome of Patients with Atypical Endometrial Hyperplasia and Endometrial Cancer after Fertility-Preserving Treatment: A Multicenter Retrospective Study. Front. Oncol. 2021, 11, 808881.
    89. 89. Yamagami, W.; Susumu, N.; Makabe, T.; et al. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J. Gynecol. Oncol. 2018, 29, e21.
    90. 90. Cheng, Y.; Dong, Y.; Yang, B.; et al. Pregnancy complications and outcomes in patients with early endometrial cancer or atypical hyperplasia after fertility-sparing treatment. J. Gynecol. Oncol. 2025, 36, e111.
    91. 91. Lin, C.Y.; Chao, A.; Wang, T.H.; et al. Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells. Oncotarget 2016, 7, 60038–60052.
    ×